This whitepaper provides a clear and concise overview of the Act’s background, intent, and the key pieces of regulatory legislation it is set to influence. It looks into critical areas such as clinical trials and Supplementary Protection Certificate (SPC) extensions, highlighting the improvements expected to accelerate biotech innovation and streamline development pathways across the EU.
Beyond policy, the paper translates these changes into practical implications for sponsors. From regulatory affairs and quality assurance to supply chain, technical operations, and launch readiness, it outlines what organisations need to consider to remain compliant and competitive. It also examines how the evolving landscape will impact EU market strategy and territory expansion, helping companies position themselves effectively in a rapidly shifting environment.
The whitepaper is a collaboration between Arex Advisor and Supply Chain Operations.
Arex has also published a shorter summary of the Biotech Act.
More insights about EU legislation reforms:
EU reaches landmark agreement on pharmaceutical legislation reform
FAST-EU: Accelerating clinical trials to boost Europe’s competitiveness
How do these changes affect you?
Our experienced specialists are ready to help you navigate the regulatory landscape!